NAV

Seralutinib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Seralutinib
DrugBank Accession Number
DB18072
Background

Not Available

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 469.545
Monoisotopic: 469.211389749
Chemical Formula
C27H27N5O3
Synonyms
  • 3-pyridinecarboxamide, n-(3-((1s)-1-((6-(3,4-dimethoxyphenyl)-2-pyrazinyl)amino)ethyl)phenyl)-5-methyl-
  • N-(3-((1s)-1-((6-(3,4-dimethoxyphenyl)-2-pyrazinyl)amino)ethyl)phenyl)-5-methyl-3-pyridinecarboxamide
External IDs
  • GB-002
  • GB002
  • PK 10571
  • PK-10571
  • PK10571
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
3P63ZTE3OY
CAS number
1619931-27-9
InChI Key
JHJNPOSPVGRIAN-SFHVURJKSA-N
InChI
InChI=1S/C27H27N5O3/c1-17-10-21(14-28-13-17)27(33)31-22-7-5-6-19(11-22)18(2)30-26-16-29-15-23(32-26)20-8-9-24(34-3)25(12-20)35-4/h5-16,18H,1-4H3,(H,30,32)(H,31,33)/t18-/m0/s1
IUPAC Name
N-{3-[(1S)-1-{[6-(3,4-dimethoxyphenyl)pyrazin-2-yl]amino}ethyl]phenyl}-5-methylpyridine-3-carboxamide
SMILES
COC1=CC=C(C=C1OC)C1=CN=CC(N[C@@H](C)C2=CC=CC(NC(=O)C3=CN=CC(C)=C3)=C2)=N1

References

General References
Not Available
ChemSpider
81367651
ChEMBL
CHEMBL4650333

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Not Yet RecruitingTreatmentPulmonary Arterial Hypertension (PAH)1
3RecruitingTreatmentPulmonary Arterial Hypertension (PAH)1
2CompletedTreatmentPulmonary Arterial Hypertension (PAH)1
2RecruitingTreatmentPulmonary Arterial Hypertension (PAH)1
1CompletedTreatmentPulmonary Arterial Hypertension (PAH)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP3.85Chemaxon
pKa (Strongest Acidic)15.06Chemaxon
pKa (Strongest Basic)4Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count7Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area98.26 Å2Chemaxon
Rotatable Bond Count8Chemaxon
Refractivity137.39 m3·mol-1Chemaxon
Polarizability51.54 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at September 08, 2023 21:41 / Updated at September 12, 2023 18:33